Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma

Liver Transplantation

Volumn 22, Issue 5, 2016, Pages 627-634

  Yanik, Elizabeth L ^a   Chinnakotla, Srinath ^b   Gustafson, Sally K ^c   Snyder, Jon J ^b,c   Israni, Ajay K ^b,c   Segev, Dorry L ^c,d   Engels, Eric A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ALL CAUSE MORTALITY; ARTICLE; CADAVER DONOR; CANCER MORTALITY; CANCER RECURRENCE; CARDIOVASCULAR DISEASE; DISEASE CLASSIFICATION; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MILAN CRITERIA; MORTALITY; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VOLUME; CARCINOMA, HEPATOCELLULAR; DRUG ADMINISTRATION; END STAGE LIVER DISEASE; LIVER NEOPLASMS; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; SEVERITY OF ILLNESS INDEX;

CARCINOMA, HEPATOCELLULAR; DRUG ADMINISTRATION SCHEDULE; END STAGE LIVER DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SEVERITY OF ILLNESS INDEX; SIROLIMUS; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME;

EID: 84964758368     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24395     Document Type: Article

References (28)

1. Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients. United States Organ Transplantation: OPTN & SRTR Annual Data Report 2011. Liver. Rockville, MD: Division of Transplantation, Healthcare Systems Bureau,Health Resources and Services Administration, US Department of Health and Human Services; 2012.
2. Cabrera R, Nelson DR,. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2010; 31: 461-476.
3. Toso C, Mentha G, Majno P,. Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence. Am J Transplant 2011; 11: 2031-2035.
4. Schlitt HJ, Neipp M, Weimann A, Oldhafer KJ, Schmoll E, Boeker K, et al., Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol 1999; 17: 324-331.
5. Castroagudín JF, Molina-Pérez E, Ferreiro-Iglesias R, Abdulkader I, Otero-Antón E, Tomé S, Varo-Pérez E,. Late recurrence of hepatocellular carcinoma after liver transplantation: is an active surveillance for recurrence needed? Transplant Proc 2012; 44: 1565-1567.
6. Faivre S, Kroemer G, Raymond E,. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5: 671-688.
7. Bjornsti MA, Houghton PJ,. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4: 335-348.
8. Zhou Q, Lui VW, Yeo W,. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol 2011; 7: 1149-1167.
9. Zhou L, Huang Y, Li J, Wang Z,. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol 2010; 27: 255-261.
10. Massoud O, Wiesner RH,. The use of sirolimus should be restricted in liver transplantation. J Hepatol 2012; 56: 288-290.
11. McKenna GJ, Trotter JF,. Sirolimus - it doesn't deserve its bad Rap(a). J Hepatol 2012; 56: 285-287.
12. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM,. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51: 1237-1243.
13. Chinnakotla S, Davis GL, Vasani S, Kim P, Tomiyama K, Sanchez E, et al., Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2009; 15: 1834-1842.
14. Menon KV, Hakeem AR, Heaton ND,. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2013; 37: 411-419.
15. Zhou J, Wang Z, Wu ZQ, Qiu SJ, Yu Y, Huang XW, et al., Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc 2008; 40: 3548-3553.
16. Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, Kam I,. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008; 14: 633-638.
17. Leppke S, Leighton T, Zaun D, Chen SC, Skeans M, Israni AK, et al., Scientific Registry of Transplant Recipients: collecting, analyzing, and reporting data on transplantation in the United States. Transplant Rev (Orlando) 2013; 27: 50-56.
18. IMS Health. www.imshealth.com. Accessed February 10, 2016.
19. Lin G, So Y, Johnston G,. Analyzing survival data with competing risks using SAS Software. SAS Global Forum 2012 Conference, 2012. Cary, NC: SAS Institute Inc.
20. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al., Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
21. Sieghart W, Fuereder T, Schmid K, Cejka D, Werzowa J, Wrba F, et al., Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 2007; 83: 425-432.
22. Friemel J, Rechsteiner M, Frick L, Böhm F, Struckmann K, Egger M, et al., Intratumor heterogeneity in hepatocellular carcinoma. Clin Cancer Res 2015; 21: 1951-1961.
23. Geissler EK, Schnitzbauer AA, Zülke C, Lamby PE, Proneth A, Duvoux C, et al., Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation 2016; 100: 116-125.
24. Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, et al., Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 2014; 312: 57-67.
25. Klintmalm GB, Nashan B,. The role of mTOR inhibitors in liver transplantation: reviewing the evidence. J Transplant 2014; 2014: 845438.
26. Halloran PF,. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-2729.
27. Watt KD, Dierkhising R, Heimbach JK, Charlton MR,. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl 2012; 18: 1029-1036.
28. Schnitzbauer AA, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, et al., A prospective randomized, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 2010; 10: 190.